Core Viewpoint - Indivior Pharmaceuticals, Inc. has completed its redomiciliation from the UK to the US, establishing a new parent company in Delaware and renaming the previous entity to Indivior Ltd, which is now a wholly-owned subsidiary [1][2] Group 1: Redomiciliation Details - The redomiciliation was approved by Indivior shareholders during an extraordinary general meeting on December 11, 2025 [1] - Indivior PLC ordinary shares ceased trading on Nasdaq on January 23, 2026, with shareholders receiving one new common share of Indivior Pharmaceuticals, Inc. for each share held [1] Group 2: Benefits of Redomiciliation - The change in domicile is expected to enhance the benefits of its US stock listing, including compliance with SEC reporting requirements and Nasdaq exchange rules [2] - The company anticipates potential inclusion in additional US equity indices, which could strengthen its market presence [7] - Simplification of corporate governance and reduced complexity are also expected outcomes of the redomiciliation [7] Group 3: Strategic Positioning - The redomiciliation aims to further position Indivior as a US-based treatment innovator, facilitating closer collaboration with public health leaders on advancing SUBLOCADE® for opioid use disorder [7] - Indivior is committed to delivering evidence-based treatment for opioid use disorder and advancing the understanding of this condition as a chronic but treatable brain disease [5]

Core Viewpoint - Ardelyx (ARDX) shares experienced a significant increase of 15% to $7.76, reflecting strong investor confidence in the company's financial performance ahead of its fourth-quarter results [1][2] Financial Performance - Ardelyx reported impressive preliminary product revenue figures for 2025, with Ibsrela generating approximately $274 million, a 73% increase from 2024, and Xphozah generating about $104 million [2] - The upcoming quarterly earnings are expected to be $0.02 per share, unchanged from the previous year, with revenues projected at $118.08 million, a 1.7% increase from the year-ago quarter [3] Earnings Estimates - The consensus EPS estimate for Ardelyx has been revised 80% higher in the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [4] - The stock currently holds a Zacks Rank of 3 (Hold), suggesting a neutral outlook [4] Industry Comparison - Ardelyx is part of the Zacks Medical - Drugs industry, where another company, Indivior PLC (INDV), saw a 1.3% increase in its stock price but has returned -10.7% over the past month [4] - Indivior's consensus EPS estimate has increased by 10% over the past month to $0.65, reflecting a year-over-year change of +103.1% [5]

Core Insights - The recent tariff noise is impacting the market, and investors are advised to focus on long-term investment themes rather than reacting to headlines [1][7] Market Performance - In 2025, markets initially fell nearly 15% by April due to tariff fears, but those who remained invested saw a 39% rebound by year-end, highlighting the importance of long-term trends [2] Investment Opportunities - Investors should prioritize long-term growth opportunities, particularly in the AI sector, with trillions expected in infrastructure investments by 2030 [3] - Comfort Systems USA Inc. (NYSE:FIX) and Duke Energy Corp. (NYSE:DUK) are highlighted as stable investment options, with Duke trading at 17X forward earnings and offering a 3.7% dividend yield [4] Promising Sectors - Aerospace and defense sectors are expected to benefit from rising global military budgets, while small-cap biotech is positioned to gain from patent cliffs and M&A activity [5] - Notable companies in these sectors include L3 Harris Technology Inc. (NYSE:LHX) in defense and Indivior PLC (NASDAQ:INDV) and Day One Biopharmaceuticals Inc. (NASDAQ:DAWN) in biotech [5] Future Market Outlook - In 2026, investors who align with their risk tolerance and "follow the money" may find attractive entry points despite ongoing market volatility [6] - Current market conditions are turbulent due to renewed tariff threats, with the S&P 500 and Nasdaq 100 both sliding around 2%, marking their worst sessions in over three months [7][8]

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh. ...

Core Insights - Pacira BioSciences (PCRX) reported preliminary, unaudited total revenues of $196.9 million for Q4 2025, missing the Zacks Consensus Estimate of $199 million, leading to a 9.6% decline in stock price [1][5] Group 1: Product Revenues - Exparel's net product sales reached $155.8 million in Q4 2025, a 5% increase from the previous year, slightly exceeding the Zacks Consensus Estimate of $155 million [3][5] - Zilretta's net product sales were reported at $33 million, remaining flat year over year and missing the Zacks Consensus Estimate of $34.4 million [6][7] - Iovera's net product sales amounted to $7 million, an 8% increase from the year-ago quarter, but fell short of the Zacks Consensus Estimate of $7.3 million [8] Group 2: Annual Performance - For the full year 2025, Pacira BioSciences reported total revenues of $726.4 million, a 4% increase year over year, but below the Zacks Consensus Estimate of $728.8 million [9]

Core Insights - Teva Pharmaceuticals has entered a funding agreement with Royalty Pharma to receive up to $500 million for the development of its anti-IL-15 antibody, TEV-'408, which is in early-stage development for vitiligo and other autoimmune diseases [1][2] Funding Agreement Details - The agreement includes $75 million for R&D co-funding of a phase IIb vitiligo study expected to start in 2026, with an option for an additional $425 million to co-fund phase III development based on phase IIb results [2] - Teva will retain rights to the drug while being responsible for milestone payments and ongoing royalties on global net sales if the drug is approved [5][11] Strategic Benefits for Teva - The collaboration with Royalty Pharma strengthens Teva's immunology pipeline, reduces financial exposure, and accelerates the development of TEV-'408, allowing for faster clinical progression [3][4] - Teva's shares have increased by 95% over the past six months, outperforming the industry growth of 54.1% [4] Market Potential - Vitiligo is a chronic autoimmune condition with a global prevalence of 0.5% to 2%, representing a significant unmet medical need due to limited treatment options [7] - TEV-'408 aims to address both the physical and psychosocial burdens of vitiligo by targeting the IL-15 pathway responsible for immune-driven melanocyte destruction [7] Ongoing Research and Development - Teva is also evaluating TEV-'408 in a phase IIa study for celiac disease, which received Fast Track designation from the FDA in 2025 [8] - The current collaboration with Royalty Pharma marks Teva's second agreement, following a previous deal for the development of TEV-'749 for schizophrenia [9]

Market Overview - U.S. stock markets ended positively with the Nasdaq Composite, Dow Jones Industrial Average, and S&P 500 gaining 1.18%, 1.08%, and 0.93% respectively despite mid-week volatility [1] - Market direction was influenced by U.S. policy developments regarding Venezuela, enthusiasm for AI-linked technology stocks, and mixed economic data [1] Economic Indicators - The manufacturing Purchasing Managers' Index (PMI) fell to 47.9 in December 2025, the lowest since October 2024, indicating contraction [2] - Conversely, the Services PMI unexpectedly rose to 54.4 in December from 52.6 in the previous month, indicating expansion [2] - Nonfarm Payrolls increased by 50,000 jobs in December, below expectations, while the unemployment rate slightly declined to 4.4% from 4.5% in November [2] - Average Hourly Earnings increased by 3.8% year-over-year, up from 3.6% in November [2] Stock Performance - Indivior PLC shares rose 21.7% since being upgraded to Zacks Rank 1 (Strong Buy) on October 31, outperforming the S&P 500's 2% increase [4] - FormFactor, Inc. shares increased by 15.9% since its upgrade to Zacks Rank 2 (Buy) on October 31, also outperforming the S&P 500 [5] - An equal-weight portfolio of Zacks Rank 1 stocks outperformed the equal-weight S&P 500 index by 7 percentage points, returning +17.81% compared to +10.85% for the index [5] Focus List and Model Portfolios - The Zacks Focus List portfolio returned +22.1% in 2025, outperforming the S&P 500 index's +17.9% gain [12] - The Focus List has consistently outperformed the S&P 500 over various time frames, including a +22.1% return in the last year compared to +17.9% for the index [14] - The Earnings Certain Admiral Portfolio (ECAP) returned -1.67% in 2025, underperforming the S&P 500's +17.9% gain [15] - The Earnings Certain Dividend Portfolio (ECDP) returned -0.6% in 2025, also underperforming compared to the S&P 500 [19] Notable Stock Recommendations - FIGS, Inc. shares surged 56.8% since being upgraded to Outperform on November 7, significantly outperforming the S&P 500's 3.5% increase [8] - Five Below, Inc. shares increased by 21.7% since its upgrade on October 29, again outperforming the S&P 500 [8] - Mettler-Toledo International Inc. and Accenture plc saw returns of 16.6% and 16.5% respectively over the past 12 weeks [14]

Financial Guidance - Indivior PLC expects total net revenue for 2026 to be in the range of $1.125 billion to $1.195 billion, with SUBLOCADE® net revenue anticipated between $905 million and $945 million [1] - The company aims to grow SUBLOCADE net revenue by 11% at the midpoint of its guidance range, while raising adjusted EBITDA by 35% and adjusted EBITDA margin by 14 percentage points [2] Business Highlights - Indivior PLC was included in the S&P SmallCap 600® index effective December 22, 2025 [3] - The company received shareholder approval to change its domicile from the U.K. to the U.S., with the new U.S. parent company, Indivior Pharmaceuticals, Inc., expected to take effect on January 26, 2026 [3] - Indivior paid off an outstanding obligation of $295 million and concluded a legacy U.S. Department of Justice matter [3] Company Overview - Indivior PLC develops, manufactures, and sells buprenorphine-based prescription drugs for treating opioid dependence, with products including Suboxone Film, Suboxone Tablet, and Subutex Tablet [4] - The company's operations are divided into geographical segments: United States, Rest of World, and United Kingdom [4]

Core Insights - Amarin's shares increased nearly 17% following the release of preliminary sales numbers for Q4 and full-year 2025, which exceeded expectations [1][6] Financial Performance - Preliminary total revenues for Q4 2025 are expected to be between $48 million and $53 million, surpassing the Zacks Consensus Estimate of $43 million [3] - For full-year 2025, preliminary total revenues are projected to be between $212 million and $217 million, above the Zacks Consensus Estimate of $207 million [3] - The company achieved positive cash flow in Q4 2025, earlier than the previously expected timeline of 2026 [5][6] - Amarin ended 2025 with approximately $303 million in cash and investments, an increase from $287 million in Q3 2025, and remains debt-free [5][6] Cost Management and Restructuring - Restructuring costs for full-year 2025 are expected to range from $37 million to $40 million, up from the prior estimate of $30 million to $37 million [4] - Amarin has achieved approximately 50% of its planned $70 million operating expense reductions, with full benefits expected by June 2026 [4] Market Expansion - Amarin signed an exclusive long-term license and supply agreement with Recordati to commercialize Vazkepa in 59 countries, primarily in the European Union [7] - The company has established partnerships with seven experienced partners, providing access to nearly 100 markets [7] - Vascepa/Vazkepa is approved in over 50 countries and is protected by patents in Europe until 2039 [8] Stock Performance - Over the past year, Amarin's shares have risen 48.6%, compared to the industry's growth of 19.2% [5]

Core Insights - Monte Rosa Therapeutics (GLUE) experienced a 45.41% increase in share price following positive interim data from a phase-I study of its candidate MRT-8102, aimed at treating inflammatory conditions driven by NLRP3, IL-1, and IL-6 [1][6] Study Results - The phase I MRT-8102 study is a randomized, double-blind, placebo-controlled trial involving healthy volunteers and higher cardiovascular-risk subjects, focusing on safety, tolerability, pharmacokinetics, and pharmacodynamic effects [2] - Interim results showed robust activity of MRT-8102, with 48 patients in single-dose cohorts, 40 in multiple-dose cohorts, and 24 higher-risk patients completing four weeks of treatment [5] - MRT-8102 achieved approximately 80–90% NEK7 degradation across all dose levels [5][6] - High-sensitivity CRP (hsCRP) levels were reduced by 85% in the higher-risk group after four weeks, with nearly all patients reaching low-risk levels [6] Safety and Tolerability - The drug demonstrated a favorable safety profile and was well-tolerated among participants [7] Future Development Plans - Monte Rosa plans to report complete data from the GFORCE-1 study in the first half of 2026 and initiate the phase II GFORCE-2 study later in the year [8] - The company expects partner Novartis to start multiple mid-stage studies of MRT-6160 in immune-related diseases in 2026 [8] - Additional plans include presenting updated data from the ongoing phase I/II study of MRT-2359 at the ASCO Genitourinary Cancers Symposium in February 2026 and initiating the MODeFIRe-1 phase II study later in the year [9] - Monte Rosa intends to submit IND applications in 2026 for next-generation NEK7-directed MGD and a CDK2 and/or cyclin E1-directed MGD [9]